An exploratory clinical study of the renoprotective effect of empagliflozin and the verification of companion diagnostics in type 2 diabetes patients
Latest Information Update: 06 Sep 2019
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms RECOVERY
- 06 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Jan 2017 Status changed from not yet recruiting to recruiting.
- 23 Sep 2016 New trial record